갈메드 파머슈티컬스GLMD 주가

12 Health Care Stocks Moving In Friday's Pre-Market Session

♻️ 재탕Galmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 300mg

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver disease and GI oncological therapeutics, announced today major milestone results from a Phase 1 PK study in healthy subjects (Study AM-001). The overall objective of the study was to identify the dose of Aramchol meglumine (AM) administered once daily that produces similar exposure to Aramchol from 300mg Aramchol free acid (AA) tablets dosed twice daily. Single doses of AM

Galmed announces results from first-in-man pharmacokinetics study of oral formulation of Aramchol Meglumine (AM) 400mg AM increases bioavailability by ~500% in comparison to Aramchol Free Acid (AA) 300mg

Galmed Pharmaceuticals Ltd:Galmed announces results from first-in-man pharmacokinetics study of oral formulation of Aramchol Meglumine ; 400mg AM increases bioavailability by ~500% in comparison to...

Galmed Pharmaceuticals Announces Milestone Results From Phase 1 PK Study In Healthy Subjects; 400mg AM Increases Bioavailability By ~500% In Comparison To Aramchol Free Acid 300mg

Results from Study AM-001 mark a pivotal advance through the transition to a once daily lower 400mg dose of AM enabling:Production of GMP clinical batch for Galmed's upcoming clinical trialsSolidification and

[6-K] 6-K — 6-K

Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics

Tissue Dynamics Ltd. and Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver disease and GI oncological therapeutics, today announced a collaboration to develop a novel human chronic cardiac fibrosis model designed to accelerate the discovery and development of new Aramchol-based therapeutic approaches for complex fibrotic heart diseases. Cardiac fibrosis is a major driver of chronic heart failure, including long-term remod

Tissue Dynamics, Galmed Pharmaceuticals Partner To Develop Novel Human Chronic Fibrosis Model

Tissue Dynamics Ltd. and Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver disease and GI oncological therapeutics, today announced a

[6-K] 6-K — 6-K

[6-K] 6-K — 6-K

[6-K] 6-K — 6-K